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Abstract
This brief review recounts how, stimulated by the work of Geoff Burnstock, I developed biosensors that allowed direct real-time
measurement of ATP and adenosine during neural function. The initial impetus to create an adenosine biosensor came from
trying to understand howATP and adenosine-modulated motor pattern generation in the frog embryo spinal cord. Early biosensor
measurements demonstrated slow accumulation of adenosine during motor activity. Subsequent application of these biosensors
characterized real-time release of adenosine in in vitro models of brain ischaemia, and this line of work has recently led to clinical
measurements of whole blood purine levels in patients undergoing carotid artery surgery or stroke. In parallel, the wish to
understand the role of ATP signalling in the chemosensory regulation of breathing stimulated the development of ATP biosen-
sors. This revealed that release of ATP from the chemosensory areas of the medulla oblongata preceded adaptive changes in
breathing, triggered adaptive changes in breathing via activation of P2 receptors, and ultimately led to the discovery of
connexin26 as a channel that mediates CO2-gated release of ATP from cells.
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Introduction
I vividly remember the first time I heard Geoff Burnstock give
a seminar. It was in 1994, and although I had known Geoff for
quite some time, I had never heard him deliver a lecture. So,
when he came to Bristol to give a major talk, I went with great
eagerness, but also not knowing quite what to expect. What
unfolded over the course of about an hour was one of the most
inspiring lectures I had ever heard. At the time I had only a
dim, verging on nonexistent, grasp of purinergic signalling.
Geoff, at the height of his powers, convincedme, and I suspect
everyone else in the audience that the purines were pretty
much the answer to every physiological problem out there. I
was so inspired that I got into my lab the very next day and
started dabbling with ATP and adenosine. I had been running
my own independent lab for about 5 years. I was working on
the neuronal mechanisms of spinal motor pattern generation in
the frog embryo, trying to build Hodgkin-Huxley inspired
models of the circuit, so it was natural to apply ATP and
adenosine to the spinal cord and look at the consequences
for motor pattern generation. Immediately I realized that there
was something very interesting: both ATP and adenosine had
powerful but opposing actions, on the neural circuitry that
generated the swimming motor pattern. Two years of hard
work, and self-tuition in the arts of purinergic signalling, re-
sulted in a paper that described an excitatory action of ATP
(mediated via an effect of voltage gated K+ channels) and an
inhibitory action of adenosine (through inhibition of voltage
gated Ca2+ channels via A1 receptors) [1]. It was clear that the
inhibitory action of adenosine had something to do with con-
trolling the spontaneous slowing of the swimming motor pat-
tern and its eventual termination. Courtesy of Geoff’s great
lecture, and subsequent reading of the literature, I was also
aware that the adenosine might arise from conversion of
ATP that had been released into the extracellular space [2].
This led to a puzzle: if the released ATP, which was excitato-
ry, was converted to adenosine, which was inhibitory, how did
this give rise to the observed temporal control of motor pattern
generation? One way that this could arise would be if the
production of adenosine was delayed with respect to the re-
lease of ATP. In fact, there was already a mechanism in the
literature whereby ATP and ADP could inhibit the ecto-5′-
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nucleotidase that converts AMP to adenosine that could intro-
duce such a hypothesized delay [3–5]. It was these thoughts
that led me to the realization that I needed to test these ideas by
measuring the release of adenosine in real time. After further
scanning of the literature, I realized that the only way to
achieve this was to invent a biosensor for adenosine. What
follows is a not a scholarly review of purine measurements,
but a personal account of some of the science, in which I have
been involved, which flowed from the inspiration that Geoff’s
talk gave me.
Real-time measurement of adenosine
To make a biosensor for adenosine, I borrowed from nature
the enzymes that are involved in processing purines: adeno-
sine deaminase, purine nucleoside phosphorylase, and xan-
thine oxidase [6]. This cascade will successively convert
adenosine via inosine, hypoxanthine, and xanthine to uric ac-
id. Xanthine oxidase produces H2O2, which is easy to detect
electrochemically (Fig. 1a). Of course, a biosensor that in-
volves 3 enzymes will be sensitive to substrates for all 3 en-
zymes, so to test whether it specifically detected adenosine, I
utilized an inhibitor of adenosine deaminase, coformycin. To
make the biosensor, I loaded these three enzymes in aqueous
solution into a very fragile microdialysis electrode assembly
(Fig. 1b). The idea was that adenosine, released from tissue,
would diffuse through the dialysis membrane, be metabolized
by the enzymes within the electrode, and thus generate the
H2O2 for electrochemical detection via the internal electrodes
(Fig. 1b, c). This assembly, at 250 μm in diameter, was bigger
than the spinal cord I was trying to measure from (diameter
about 70 μm), and at first, I saw nothing. But one day, after
numerous attempts, I detected an adenosine signal. By chance
it turned out that the assembly I had used that day had the Pt
wire for detecting the H2O2 in a position that led to it being
right next to the spinal cord (Fig. 1c). Reliable detection of
adenosine was accomplished once I had convinced the man-
ufacturer of the microdialysis assembly to make them all with
that particular arrangement of the internal electrodes (Fig. 1d).
My recordings showed that adenosine was produced gradually
during motor activity and gave experimental support for the
hypothesis of delayed production in the extracellular space [6,
7].
I realized that the adenosine biosensor was potentially quite
useful and thought that finding a few collaborators to pursue
other questions would be interesting. So, once again, I turned
to Geoff and asked him who he thought might be worth
contacting. Geoff suggested that his colleague, Mike Spyer,
a physiologist at UCL with wide interests in autonomic con-
trol who at the time was in the Royal FreeMedical School and
had an office close to Geoff’s, would be good to talk to. This
Fig. 1 First real-time recording of adenosine during neural activity. (a)
Enzymatic cascade for the adenosine biosensor. ADase, adenosine
deaminase; PNPase, purine nucleoside phosphorylase; XO, xanthine
oxidase. (b) Image of the microdialysis electrode assembly use for the
original adenosine biosensor with schematic showing enzymes in
solution, supporting the production of H2O2 in proportion to the
concentration of adenosine (able to diffuse through the porous wall of
the electrode) which was detected by the Pt electrode held at 650 mVwith
respect to an Ag/AgCl reference. (c) Schematic of arrangement for
recording adenosine release during fictive swimming in the tadpole.
The biosensor and spinal cord are shown in cross section to show their
relative sizes. Diffusion of adenosine from the spinal cord to the biosensor
is indicated by arrows; note that the position of the Pt electrode inside the
microdialysis tube was crucial to enable reliable detection. (d) Recording
of the real-time release of adenosine during swimming acting indicated by
motor nerve activity on the ventral root (VR). Trace reproduced from
reference [6]
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was an inspired recommendation, as Mike Spyer had seen my
adenosine biosensor paper and had already written to me.
Courtesy of a recommendation from Charles Kennedy, I also
met up with Bruno Frenguelli, then at Dundee, to discuss
collaborations. My collaborations with Mike Spyer and
Bruno Frenguelli turned out to be long lasting, fun, very pro-
ductive, and instrumental in providing the scientific stimulus
to develop further the biosensor technology for adenosine and
ultimately a biosensor for ATP and other neuroactive
compounds.
Measurement of adenosine release: in vitro
stroke models to clinical studies
At the time that Bruno Frenguelli and I started to collaborate in
early 1998, Bruno’s interest was in how the brain dealt with
metabolic stress. Bruno had developed an in vitro model of a
stroke in a dish, whereby a hippocampal brain slice could be
starved of O2 (hypoxia) or in a more severe model deprived
simultaneously of O2 and glucose (“ischaemia”). Recording
of synaptic transmission within the slice (the hippocampus
with its well-understood neuronal architecture and synaptic
connectivity being very advantageous for this) allowed a
physiological read-out of the effect of hypoxia/ischaemia. It
was known fromwork of many investigators that, during hyp-
oxia/ischaemia, adenosine was released from neural tissue
[8–16]. This work mainly used microdialysis or related tech-
niques to collect perfusate and then analyze this post hoc via
HPLC—a laborious and time-consuming enterprise. Bruno
and others had pharmacological evidence in vitro that the
depression of synaptic transmission during hypoxia/
ischaemia was mediated via adenosine A1 receptors. Thus,
when we started to work together, we had a clear expectation
that we should see adenosine release during the hypoxic/
ischemic episodes. The advantage of using a biosensor was
that we could not only detect the release of adenosine but also
examine its effect on synaptic transmission in real time. Our
recordings allowed us to determine the temporal relationship
between adenosine and its action on synaptic transmission
(Fig. 2a), to show that adenosine release did not require extra-
cellular Ca2+ and that the amount of adenosine depleted with
successive hypoxic/ischaemic episodes [17, 20].
Nevertheless, although we had the best, and at the time
only, real-time method of measuring adenosine release,
our work together made us realize the limitations of what
we had. The biosensors were big and bulky, very fragile,
and difficult to use. The size and fragility meant that we
were unable to put the sensors into the tissue (something
referees of our papers were very keen for us to do)—
instead we had to lay them on top. It was these limitations
that drove development of better, smaller, more sensitive,
and faster responding biosensors. The first-generation
adenosine biosensor used a microdialysis assembly with
the enzymes being present in aqueous solution. I reasoned
that if we stuck the enzymes directly to the electrode (by
Fig. 2 Measurement of adenosine release during hypoxia/ischaemia. (a)
Real-time recording of adenosine release from a hippocampal brain slice
during a hypoxic episode (black bar). Synaptic transmission was recorded
simultaneously (fEPSP). The inset shows the recording arrangement; this
was made with the same type of microdialysis electrode as show in Fig. 1,
except that it had two barrels which could be loaded with different
enzyme combinations. Reproduced from [17]. (b) Microelectrode
biosensor recordings of adenosine release during hypoxia (black bar).
The inset shows a picture of the biosensors inserted into a hippocampal
slice (the shiny metallic portion within the slice is the sensing tip).
Measurement of purine release within the slice showed new features
such as the post-hypoxic purine efflux (occurring at arrow head).
Differential measurements between a biosensor with all three enzymes
(Ado/Ino) and one only having PNPase and XO (Ino) allowed specific
recording of the adenosine signal (Ado). Reproduced from [18]. (c)
Measurement of purines (combination of adenosine, inosine,
hypoxanthine) in arterial blood of a patient undergoing carotid
endarterectomy. Note that purines are rapidly released from the brain
when the carotid artery is cross clamped (pink box). Reproduced from
[19]
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some as yet unknown method), we would have a much
better, smaller, and more robust device.
After exploring the biosensor literature, I decided to follow
the work of Serge Cosnier [21] and utilize the pyrrole deriva-
tives he had described to make a microelectrode biosensor for
adenosine. This required organic synthesis and led to Enrique
Llaudet joining the team to make the pyrrole derivatives and
fabricate the biosensors [22]. We used these methods for
about 3 years but eventually replaced them with a silicate sol
gel methodology that we invented and which gave more reli-
able and sensitive biosensors [23]. In fact, it was our develop-
ment of the sol gel techniques that made it viable to set up a
company, Sarissa Biomedical Ltd., to make and sell biosen-
sors to the scientific community, as by now I had far more
people wishing to use these biosensors than I could possibly
collaborate with.
The microelectrode biosensors allowed us to place the bio-
sensors inside the tissue. This gave important new insights
into the production of purines during stroke-like conditions.
We were able to demonstrate that in this case (unlike the
tadpole spinal cord), adenosine was released directly and did
not arise from prior release of ATP [24]. We refined our un-
derstanding of the temporal relationship between adenosine
production and its effect on synaptic transmission and found
that not only was there progressive release of adenosine dur-
ing the ischemic episode but that reoxygenation of the tissue
greatly accelerated purine release [18, 24] (Fig. 2b). This had
not been well described before, but might contribute to the
phenomenon of reactive hyperaemia [25] or indeed reperfu-
sion injury [26], as the enhanced purine release would give
rise to increased free radical production via H2O2 from the
actions of endogenous xanthine oxidase.
By now we realized that the release of purines during
in vitro stroke models might be paralleled by similar observa-
tions in the human brain during actual strokes and that aden-
osine and the purines might serve as sensitive indicators of
human cerebral ischemia. However, the biosensors that we
used for the physiological experiments were not sufficiently
selective for measuring purines in blood, meaning that they
were not suitable for any clinical studies. To address this issue,
Faming Tian and I developed a next-generation biosensor that
had an electrochemical mediator to provide excellent selectiv-
ity against electroactive interferences in blood opening the
way for clinical applications [27]. Sarissa Biomedical has
proven crucial in developing the technology further and thus
providing a way to translate our advances in purine biosensing
into practical applications. In 2017, via a collaboration with
Chris Imray, a vascular surgeon at the University Hospitals of
Coventry and Warwickshire, we showed that purines are re-
leased from the brain and detectable in the arterial blood of
patients undergoing elective carotid artery surgery (and hence
subjected to temporary unilateral cerebral hypoxia/ischaemia)
[19] (Fig. 2c). A first trial of a very early prototype purine
biosensing device “SMARTCap” showed, in a reasonably
large cohort, that the purines of stroke patients are elevated
compared with healthy controls and patients with mimicking
nonstroke conditions [28]. Further trials of the latest prototype
device “SMARTChip” are continuing to test the diagnostic
accuracy of purines as an aid to detecting stroke.
Microelectrode biosensors for ATP:
chemosensory control of breathing
My continued collaboration with Mike Spyer provided a spur
to develop a biosensor for ATP. As Mike had obtained evi-
dence that linked ATP signalling to the chemosensory control
of breathing [29, 30], the ability to measure ATP release from
the chemosensory nuclei in the medulla oblongata was an
urgent priority. In developing an ATP biosensor, I had deter-
mined that the enzymatic cascade glycerol kinase and
glycerol-3-phosphate oxidase would be advantageous
(Fig. 3a) [34]. This cascade is sensitive to ATP, if glycerol is
provided in the medium, and over the course of many studies,
we have found that a concentration of glycerol sufficient to
saturate the enzyme is well tolerated by tissue. However, we
found it very difficult to find conditions that allowed entrap-
ment of these enzymes on a microelectrode while retaining
sufficient sensitivity to make a useful ATP biosensor. We
eventually solved this problem with our new sol gel deposi-
tion method [35], and returned to work with Mike Spyer, who
had now been joined by Alex Gourine, on the problem of CO2
chemosensitivity and the control of breathing.
Very quickly, we found that during a hypercapnic ep-
isode, ATP was released from proscribed areas of the
ventral medullary surface that corresponded to the regions
that had been linked to pH/CO2 chemosensitivity [31].
Crucially the ATP was released before any adaptive
change in breathing, suggesting a causal role between
ATP release and the increase in minute ventilation (Fig.
3b). This causal relation was confirmed through use of
ATP receptor antagonists [31]. Subsequent work on this
problem by Alex Gourine has highlighted an important
role of astrocytes in the detection of pH and subsequent
release of ATP [36, 37]. In my lab, we looked further at
the mechanisms of ATP release and identified that this
occurred through hemichannels of the gap junction pro-
tein connexin26 (Cx26) (Fig. 3c). We were able to link
Cx26 to the chemosensory control of breathing with phar-
macological tools [32]. However, we found that Cx26
seemed to respond directly to CO2 rather than pH [32,
33]. Subsequent mutational analysis revealed the key res-
idues involved and a potential mechanism that involved a
proposed carbamylation of a specific lysine residue in
Cx26 by CO2 [38]. Cx26 is thus a CO2-gated channel
capable of releasing ATP. We have recently used our
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structural understanding of how CO2 interacts with Cx26
to develop a dominant negat ive cons t ruct tha t
coassembles with endogenous wild-type Cx26 to remove
CO2 sensitivity from the resulting heteromeric channel
[39]. This genetic approach has allowed us to demonstrate
that direct CO2 detection via Cx26 contributes about half
of the adaptive response to hypercapnia generated by the
central chemosensors. There is a population of specialized
glial cells present in a circumscribed nucleus—the caudal
parapyramidal area that directly detect CO2 via Cx26 and
regulate breathing via the release of ATP [39]. Very re-
cently, we have taken this down to the atomic level by
solving cryoEM structures for Cx26 at different levels of
PCO2 to directly demonstrate the carbamylation mecha-
nism and understand the conformational changes trigged
by CO2-binding that lead to channel gating [40].
In giving this personal account, I have tried to show
that, like all great scientists, Geoff’s work had far reaching
effects on the science of others. For me, it is how Geoff’s
inspirational lecture some 26 years ago, and his larger than
life effect on the field of purinergic signalling, inspired me
to follow an interlinked thread of scientific exploration. At
one end of the scientific spectrum, this initial spark led to
development of biosensors to analyze purine release and
now extends to their application in the clinical diagnosis of
stroke, and at the other end of the spectrum, a sub-2 Å
structure of the protein that acts as a receptor for CO2 can
release ATP in response to fluctuations of PCO2 and plays
a key role in vertebrate physiology.
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Fig. 3 Real-time measurement of ATP release with ATP microelectrode
biosensors. (a) Enzymatic cascade for the detection of ATP. GKase,
glycerol kinase; G3Pox, glycerol-3-phosphate oxidase. This cascade is
sensitive only to ATP if glycerol concentrations are at least 0.5 mM. (b)
Measurement of ATP release during hypercapnia from the ventral surface
of the medulla oblongata of anaesthetized artificially ventilated rat. Note
that ATP release occurs before the enhancement of breathing as indicated
by the phrenic nerve recording (PNG, arrow on ATP biosensor trace and
dotted line). End tidal (ET) CO2 is also shown. Modified from [31]. (c)
In vitro models of hypercapnic ATP release. Isolated ventral medullary
slice showing ATP release from a caudal region located next to the
pyramids (py) and XIIth nerve (XII), but not from a much more lateral
position. BA -basilar artery. Modified from [32]. CO2-dependent ATP
release can be recapitulated in HeLa cells that express connexin26 (Cx26)
but nor parental HeLa cells that do not express this connexin (modified
from [33]). Red bars indicate period of hypercapnia (60 mmHg PCO2)
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